|
||||||
|
Datasets with Acute_lymphoblastic_leukemia |
 The duplicated datasets indicate that this dataset include both pre-treatment and post-treatment samples, and partial analyses were conducted on each of the two timepoints. The dataset page shows more informations, and the analysis results of this dataset. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint |
GSE197268_Axi-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | axi-cel (CAR-T) | post |
GSE197268_Axi-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | axi-cel (CAR-T) | pre |
GSE153697 | patients | Bone marrow aspirate | Acute lymphoblastic leukemia | Relapsed B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | anti-CD19 CAR-T | NA |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | tisa-cel (CAR-T) | post |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | tisa-cel (CAR-T) | pre |
GSE158457 | PDX cells | Cell line | Acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (ALL) | Targeted therapy | dasatinib | NA |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |